Modeling the allosteric modulation of CCR5 function by Maraviroc

Drug Discovery Today: Technologies

Volumn 10, Issue 2, 2013, Pages

  Lagane, Bernard ^a   Garcia Perez, Javier ^b   Kellenberger, Esther ^c  

^a INSTITUT PASTEUR   (France)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MARAVIROC;

ALLOSTERISM; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; LIGAND BINDING; MOLECULAR MODEL; PROTEIN FUNCTION; REVIEW;

ALLOSTERIC REGULATION; ANIMALS; CYCLOHEXANES; HIV FUSION INHIBITORS; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, CCR5; TRIAZOLES;

EID: 84879888598     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.07.011     Document Type: Review

References (45)

1. M.M. Lederman Biology of CCR5 and its role in HIV infection and treatment JAMA 296 2006 815 826
2. R. Liu Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection Cell 86 1996 367 377
3. J.K. Lim CCR5: no longer a good for nothing gene-chemokine control of West Nile virus infection Trends Immunol. 27 2006 308 312
4. A. Telenti Safety concerns about CCR5 as an antiviral target Curr. Opin. HIV AIDS 4 2009 131 135
5. J. Garcia-Perez Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5) J. Biol. Chem. 286 2011 33409 33421
6. P. Cannon, and C. June Chemokine receptor 5 knockout strategies Curr. Opin. HIV AIDS 6 2011 74 79
7. J.M. Jacobson Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults J. Infect. Dis. 198 2008 1345 1352
8. H. Gaertner Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide Proc. Natl. Acad. Sci. U. S. A. 105 2008 17706 17711
9. J.M. Escola CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network J. Biol. Chem. 285 2010 41772 41780
10. M. Mack Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity J. Exp. Med. 187 1998 1215 1224
11. M. Baba A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity Proc. Natl. Acad. Sci. U. S. A. 96 1999 5698 5703
12. M. Baba TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans Antimicrob. Agents Chemother. 49 2005 4584 4591
13. K. Maeda Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro J. Virol. 78 2004 8654 8662
14. F. Maltez Recent advances in antiretroviral treatment and prevention in HIV-infected patients Curr. Opin. HIV AIDS 6 Suppl. 1 2011 S21 S30
15. W. Kromdijk Treatment of HIV infection with the CCR5 antagonist maraviroc Expert Opin. Pharmacother. 11 2010 1215 1223
16. J. Garcia-Perez New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection J. Biol. Chem. 286 2011 4978 4990
17. V.M. Muniz-Medina The relative activity of function sparing HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? Mol. Pharmacol. 75 2009 490 501
18. M. Baba Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652 Antimicrob. Agents Chemother. 51 2007 707 715
19. J.C. Tilton A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5 J. Virol. 84 2010 10863 10876
20. M. Westby Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry J. Virol. 81 2007 2359 2371
21. T. Kenakin G protein coupled receptors as allosteric proteins and the role of allosteric modulators J. Recept. Signal Transduct. Res. 30 2010 313 321
22. D.J. Scholten Pharmacological modulation of chemokine receptor function Br. J. Pharmacol. 165 2012 1617 1643
23. C. Watson The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor Mol. Pharmacol. 67 2005 1268 1282
24. M.A. Hanson, and R.C. Stevens Discovery of new GPCR biology: one receptor structure at a time Structure 17 2009 8 14
25. M.G. Paterlini Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity Biophys. J. 83 2002 3012 3031
26. I. Kufareva Status of GPCR modeling and docking as reflected by community-wide GPCR dock 2010 assessment Structure 19 2011 1108 1126
27. B. Wu Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 330 2010 1066 1071
28. C. Govaerts The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation J. Biol. Chem. 276 2001 13217 13225
29. M.C. Peeters Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation Trends Pharmacol. Sci. 32 2011 35 42
30. G. Kothandan Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study PLoS ONE 7 2012 e32864
31. M. Metz Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach J. Am. Chem. Soc. 133 2011 16477 16485
32. J. Labrecque HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay Virology 413 2011 231 243
33. C. de Graaf, and D. Rognan Customizing G protein-coupled receptor models for structure-based virtual screening Curr. Pharm. Des. 15 2009 4026 4048
34. A. Grunbeck Genetically encoded photo-cross-linkers map the binding site of an allosteric drug on a G protein-coupled receptor ACS Chem. Biol. 7 2012 967 972
35. E. Kellenberger Identification of non-peptide CCR5 receptor agonists by structure-based virtual screening J. Med. Chem. 50 2007 1294 1303
36. P.A. Stupple An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5- isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl) -8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798) J. Med. Chem. 54 2011 67 77
37. H. Tang Do crystal structures obviate the need for theoretical models of GPCRs for structure-based virtual screening? Proteins: Struct. Funct. Bioinf. 80 2012 1503 1521
38. R. Kondru Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists Mol. Pharmacol. 73 2008 789 800
39. R. Berro Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors J. Virol. 85 2011 8227 8240
40. C. Blanpain Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies Mol. Biol. Cell 13 2002 723 737
41. J.Y. Springael Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers Mol. Pharmacol. 69 2006 1652 1661
42. J.Y. Springael Allosteric properties of G protein-coupled receptor oligomers Pharmacol. Ther. 115 2007 410 418
43. C.G. Anastassopoulou Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41 Proc. Natl. Acad. Sci. U. S. A. 106 2009 5318 5323
44. L.T. Da, and Y.D. Wu Theoretical studies on the interactions and interferences of HIV-1 glycoprotein gp120 and its coreceptor CCR5 J. Chem. Inf. Model. 51 2011 359 369
45. V.I. Perez-Nueno Clustering and classifying diverse HIV entry inhibitors using a novel consensus shape-based virtual screening approach: further evidence for multiple binding sites within the CCR5 extracellular pocket J. Chem. Inf. Model. 48 2008 2146 2165